null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

null

-0.21x Total Debt / Equity (Negative equity)

Moderate-high; FCHS carries variable-rate debt on its credit facility, a 200bps rate rise likely adds ~$0.5-1M annual interest expense, pressuring thin EBITDA margins

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Domestic-only operations; primary chokepoints are medical supply distributors (e.g., Henry Schein) and orthopedic implant manufacturers concentrated in U.S. Midwest manufacturing

null

Nearly 100% U.S. domestic revenue concentrated in Florida; negligible sovereign currency devaluation risk as no material international revenue markets exist

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on a small number of orthopedic and pain management implant suppliers; switching costs exist but substitutes available; no single vendor likely exceeds 30% but top-3 may collectively exceed 60%

Cloud infrastructure termination would cause moderate disruption to billing and EHR systems but core clinical operations (in-person visits, procedures) would continue; recovery estimated within 60-90 days

Secondary administrative/billing workflows hosted on-premise or via healthcare-specific SaaS vendors (e.g., Modernizing Medicine); cloud dependency is partial, not existential

Moderate API coupling risk via EHR platform integrations; switching EHR vendors would cost $500K-$2M and 12-18 months of disruption, creating meaningful but not insurmountable lock-in

Low Howey Test risk; revenue model is direct fee-for-service medical care delivery, not an investment contract; no passive profit expectation from token or pooled enterprise

Very High

Moderate HIPAA exposure is primary; CCPA applies to California patients marginally; GDPR exposure negligible given no EU operations; PHI breach risk is the dominant compliance liability

Low antitrust risk; FCHS is a small regional healthcare operator in Florida with sub-1% market share in orthopedics and spine; no market-dominant position to trigger scrutiny

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Predominantly transactional fee-for-service (~85-90%); some recurring revenue from managed care contracts and retainer-based ancillary services (~10-15%); low recurring revenue base

Primary monetization via insurance reimbursement (Medicare, Medicaid, private payers) per procedure/visit; secondary via ancillary services (imaging, PT, surgery center facility fees)

Pricing largely dictated by payer contracts and CMS fee schedules; limited independent pricing power; reimbursement rate cuts of 5-10% would materially compress margins given high fixed costs

Low; 2/5 pricing power rating — reimbursement rates set externally by CMS and private payers; company is price-taker not price-setter in core service lines

0.7% Gross Margin (Thin (<20%))

Low free-rider risk; services require in-person clinical delivery with direct billing; however, patient churn to competing orthopedic/spine practices is moderate given low switching cost for patients

Revenue growth is largely headcount-linear; doubling revenue requires proportional addition of physicians, PAs, and clinical staff; physician recruitment is the primary bottleneck and cost driver

High marginal cost of growth; each new revenue dollar requires physician/clinician hiring, facility lease, and medical equipment; limited operating leverage until fixed-cost thresholds are absorbed

null

At 10x scale, CAC would rise substantially due to physician scarcity in Florida; unit economics improve modestly via fixed-cost leverage on facility/admin but physician compensation remains ~55-65% of revenue

No meaningful network effects; patient volume does not create compounding value for other patients; physician reputation drives referrals but this is linear, not exponential

-172.0% Return on Assets (Negative equity)

Moderate recession resistance (Tier 2); orthopedic and spine procedures include both elective (recession-sensitive) and medically necessary (recession-resistant) components; ~40% elective exposure

Individual patients (Medicare/Medicaid and commercially insured) seeking orthopedic, spine, and pain management care in Brevard County and Melbourne, Florida region

Third-party payers (Medicare ~40-45% of revenue, private insurers ~40%); high payer concentration in Medicare creates significant regulatory and reimbursement cut risk as secondary customer segment

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

7.9% CapEx / Revenue (Moderate-CapEx)

0001416876

FCHS